Medico Remedies Faces Financial Challenges Amid Declining Sales and Stake Reduction in Q2 FY24

Medico Remedies, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation adjustment that reflects its current market dynamics. The company has reported a challenging financial performance for the second quarter of FY24, with notable declines in key metrics. Operating cash flow reached its lowest point at Rs 2.68 crore, while net sales fell to Rs 39.35 crore, marking a year-over-year decrease of 7.11%. Additionally, the company's PBDIT also hit a low of Rs 2.42 crore. Despite these challenges, the stock is technically positioned within a bullish range, showing some positive movement since late January 2025. However, the company's return on capital employed (ROCE) stands at a modest 14.77%, indicating limited profitability relative to its capital base. Furthermore, a decrease in promoter stake by 6.51% over the last quarter raises questions about management confidence. Overall, Medico Remedies has underperformed the broader market, with a return of -18.77% over the past year, contrasting sharply with the BSE 500's gain of 7.28%. This evaluation adjustment highlights the complexities surrounding the stock's current standing in the market. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.